The estimated Net Worth of Alfred Altomari is at least $2.77 Million dollars as of 26 August 2022. Mr. Altomari owns over 50,000 units of Agile Therapeutics Inc stock worth over $97,158 and over the last 12 years he sold AGRX stock worth over $1,368,900. In addition, he makes $1,301,370 as Chairman of the Board and Chief Executive Officer at Agile Therapeutics Inc.
Alfred has made over 25 trades of the Agile Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of AGRX stock worth $22,500 on 26 August 2022.
The largest trade he's ever made was exercising 94,599 units of Agile Therapeutics Inc stock on 20 August 2020 worth over $166,494. On average, Alfred trades about 8,133 units every 43 days since 2013. As of 26 August 2022 he still owns at least 64,343 units of Agile Therapeutics Inc stock.
You can see the complete history of Mr. Altomari stock trades at the bottom of the page.
Alfred Altomari serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. Altomari served as our President and Chief Executive Officer from 2010 to 2016. Previously, Mr. Altomari served as our Executive Chairman from 2004 to 2010. From 2008 to September 2010, Mr. Altomari was also a consultant. From 2003 to 2008, Mr. Altomari held multiple senior management positions at Barrier Therapeutics, Inc., including Chief Commercial Officer, Chief Operating Officer, and Chief Executive Officer. In 2008, in his role as Chief Executive Officer and as a member of Barrier's board of directors, Mr. Altomari completed the successful sale of Barrier to Stiefel Laboratories, which was subsequently acquired by GlaxoSmithKline plc. From 1982 to 2003, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson & Johnson. Mr. Altomari also serves on the board of directors of Insmed Inc. and Recro Pharma, Inc. Mr. Altomari received an M.B.A. from Rider University and his B.S. from Drexel University. He currently serves on LeBow College of Business Advisory Board and the Board of the Charles D. Close School of Entrepreneurship at Drexel University. He currently is a member of the Board of Directors for TASK (Trenton Area Soup Kitchen).
As the Chairman of the Board and Chief Executive Officer of Agile Therapeutics Inc, the total compensation of Alfred Altomari at Agile Therapeutics Inc is $1,301,370. There are no executives at Agile Therapeutics Inc getting paid more.
Alfred Altomari is 61, he's been the Chairman of the Board and Chief Executive Officer of Agile Therapeutics Inc since 2019. There are 9 older and 8 younger executives at Agile Therapeutics Inc. The oldest executive at Agile Therapeutics Inc is Ajit Shetty, 73, who is the Independent Director.
Alfred's mailing address filed with the SEC is 500 COLLEGE ROAD EAST, SUITE 310, , PRINCETON, NJ, 08540.
Over the last 10 years, insiders at Agile Therapeutics Inc have traded over $2,369,944 worth of Agile Therapeutics Inc stock and bought 24,967,253 units worth $79,522,957 . The most active insiders traders include Advisors Llcperceptive Life..., Ab Investor, and Capital Iii Llc Care Capita.... On average, Agile Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $1,032,678. The most recent stock trade was executed by Alfred Altomari on 26 August 2022, trading 50,000 units of AGRX stock currently worth $22,500.
agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.
Agile Therapeutics Inc executives and other stock owners filed with the SEC include: